Endeavor BioMedicines inks $62m Series A
Endeavor BioMedicines, a developer of new treatments targeting the underlying causes of pulmonary fibrosis, has raised $62 million in Series A financing.
Endeavor BioMedicines, a developer of new treatments targeting the underlying causes of pulmonary fibrosis, has raised $62 million in Series A financing.
Copyright PEI Media
Not for publication, email or dissemination